HeartBeam CEO Named to Company’s Board of Directors

Robert Eno can add another new title to his name.

HeartBeam Inc. has appointed Eno—the company’s current CEO—to its Board of Directors. This is the third title Eno has gained since his hire 28 months ago.

As the company continues its march towards commercial readiness, the board elected to expand from eight to nine members to accommodate Eno’s addition.

“Rob’s deep expertise in sales and go-to-market strategies perfectly complements the diverse skillset and experience of the board and strengthens our strategic oversight as we move toward commercialization and long-term growth,” Board Executive Chairman Rich Ferrari said. “We are confident that Rob’s perspective will be instrumental in helping HeartBeam achieve its vision of delivering powerful cardiac insights wherever the patient is.”

Eno joined HeartBeam as president in January 2023 and was appointed CEO in October 2024. With more than 30 years of experience in the medtech industry, he has a proven track record of developing markets and launching disruptive medical technologies. His leadership has been instrumental as HeartBeam prepares to commercialize its 3D ECG technology, which captures the heart’s electrical signals in three non-coplanar directions and then synthesizes these signals into a 12-lead ECG.

HeartBeam received U.S. Food and Drug Administration (FDA) clearance for its patented 3D ECG technology in December 2024 and submitted an FDA application for the 12-lead ECG synthesis software in January. The company plans to initiate commercialization upon receiving FDA clearance for the 12-lead ECG synthesis software. Earlier this year, the company initiated an Early Access Program to obtain important feedback on the end-to-end clinical workflow, ensure operational readiness, and establish an early adopter funnel.

“I am honored to join the HeartBeam Board as we are on the brink of bringing HeartBeam’s novel technology to market,” Eno stated. “I look forward to working closely with my fellow board members as we leverage our diverse expertise to drive the company’s commercial success and accelerate the company’s mission to transform the way cardiac health is managed.”

Before joining HeartBeam, Eno was CEO of Preview Medical, a diagnostic equipment company developing real-time, in vivo tissue classification for solid tumor cancers using machine learning and proprietary optical signals. He also held senior marketing and sales leadership roles at companies including HeartFlow, OptiMedica, NeoGuide Systems, and Avantec Vascular.

Eno earned an MBA from the Stanford Graduate School of Business and a bachelor of arts degree with Honors and Distinction, from Stanford University.​

HeartBeam Inc. is a medical technology company creating the first ever cable-free device capable of collecting ECG signals in 3D, from three non-co-planar directions, and synthesizes the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care—all outside of a medical facility, redefining the future of cardiac health management. The company holds 14 U.S. and four international issued patents related to technology enablement.